Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
Blood Cancer Journal, Published online: 12 January 2023; doi:10.1038/s41408-023-00787-wProlyl-tRNA synthetase as a novel therapeutic target in multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 12, 2023 Category: Hematology Authors: Keiji Kurata Anna-James Bott Mark A. Tye Leona Yamamoto Mehmet K. Samur Yu-Tzu Tai James Dunford Catrine Johansson Filiz Senbabaoglu Martin Philpott Charlotte Palmer Karthik Ramasamy Sarah Gooding Mihaela Smilova Giorgia Gaeta Manman Guo John C. Christian Source Type: research
Extreme body mass index and survival in newly diagnosed multiple myeloma patients
Blood Cancer Journal, Published online: 12 January 2023; doi:10.1038/s41408-022-00782-7Extreme body mass index and survival in newly diagnosed multiple myeloma patients (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 12, 2023 Category: Hematology Authors: Urvi A. Shah Karissa Whiting Sean Devlin Rachel Ershler Bindu Kanapuru David J. Lee Sabrin Tahri Thomas Gwise Even H. Rustad Sham Mailankody Alexander M. Lesokhin Dickran Kazandjian Francesco Maura Daniel Auclair Brenda M. Birmann Saad Z. Usmani Nicole Go Source Type: research
Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Blood Cancer Journal, Published online: 11 January 2023; doi:10.1038/s41408-022-00763-wPevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 11, 2023 Category: Hematology Authors: Pallawi Torka Swetha Kambhampati Lu Chen Xiaoguang Wang Canping Chen Dan Vuong Hanjun Qin Alexandra Muir Kirsten Orand Ivana Borja D. Lynne Smith Alex F. Herrera Stephen E. F. Spurgeon Byung Park Lionel D. Lewis Francisco Hernandez-Ilizaliturri Zheng Xia Source Type: research
Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
Blood Cancer Journal, Published online: 11 January 2023; doi:10.1038/s41408-023-00785-yDefining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 11, 2023 Category: Hematology Authors: Utkarsh Goel Charalampos Charalampous Prashant Kapoor Moritz Binder Francis K. Buadi David Dingli Angela Dispenzieri Amie Fonder Morie A. Gertz Wilson I. Gonsalves Suzanne R. Hayman Miriam A. Hobbs Yi L. Hwa Taxiarchis Kourelis Martha Q. Lacy Nelson Leung Source Type: research
Low-dose PTCy plus low-dose ATG as GVHD prophylaxis after UD-PBSCT for hematologic malignancies: a prospective, multicenter, randomized controlled trial
Blood Cancer Journal, Published online: 11 January 2023; doi:10.1038/s41408-022-00771-wLow-dose PTCy plus low-dose ATG as GVHD prophylaxis after UD-PBSCT for hematologic malignancies: a prospective, multicenter, randomized controlled trial (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 11, 2023 Category: Hematology Authors: Yingling Zu Ruirui Gui Zhen Li Juan Wang Yanli Zhang Fengkuan Yu Huifang Zhao Xinrong Zhan Zhongliang Wang Pengtao Xing Xianjing Wang Huili Wang Yongping Song Jian Zhou Source Type: research
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
Blood Cancer Journal, Published online: 05 January 2023; doi:10.1038/s41408-022-00778-3One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 5, 2023 Category: Hematology Authors: Jos é Luis Piñana Lourdes Vazquez Marisa Calabuig Lucia L ópez-Corral Gabriel Martin-Martin Lucia Villalon Gabriela Sanz-Linares Venancio Conesa-Garcia Andr és Sanchez-Salinas Beatriz Gago Ana Facal Irene Risco-G álvez Mar ía T. Olave Ildefonso Espi Source Type: research
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review
Blood Cancer Journal, Published online: 05 January 2023; doi:10.1038/s41408-022-00779-2The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 5, 2023 Category: Hematology Authors: Hira Mian Arleigh McCurdy Smith Giri Shakira Grant Bram Rochwerg Erica Winks Ashley E. Rosko Monika Engelhardt Charlotte Pawlyn Gordon Cook Graham Jackson Sara Bringhen Thierry Facon Alessandra Larocca Sonja Zweegman Tanya M. Wildes Source Type: research
Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma
Blood Cancer Journal, Published online: 05 January 2023; doi:10.1038/s41408-022-00777-4Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 5, 2023 Category: Hematology Authors: Aldo A. Acosta-Medina Isla McKerrow Johnson Radhika Bansal Matthew Hathcock Saad J. Kenderian Urshila Durani Arushi Khurana Yucai Wang Jonas Paludo Jose C. Villasboas N. Nora Bennani Patrick B. Johnston Stephen M. Ansell Yi Lin Hassan B. Alkhateeb Source Type: research
Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment
Blood Cancer Journal, Published online: 04 January 2023; doi:10.1038/s41408-022-00773-8Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 4, 2023 Category: Hematology Authors: Kelly von Beck Troy von Beck P. Brent Ferrell Jr Alexander G. Bick Ashwin Kishtagari Source Type: research
Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study
Blood Cancer Journal, Published online: 04 January 2023; doi:10.1038/s41408-022-00766-7Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 4, 2023 Category: Hematology Authors: Nicolas Boissel Sabina Chiaretti Cristina Papayannidis Josep-Maria Ribera Renato Bassan Andrey N. Sokolov Naufil Alam Alessandra Brescianini Isabella Pezzani Georg Kreuzbauer Gerhard Zugmaier Robin Fo à Alessandro Rambaldi Source Type: research
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
Blood Cancer Journal, Published online: 04 January 2023; doi:10.1038/s41408-022-00772-9Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 4, 2023 Category: Hematology Authors: Elias K. Mai Stefanie Huhn Kaya Miah Alexandra M. Poos Christof Scheid Katja C. Weisel Uta Bertsch Markus Munder Oscar Berlanga Dirk Hose Anja Seckinger Anna Jauch Igor W. Blau Mathias H änel Hans J. Salwender Axel Benner Marc S. Raab Hartmut Goldschmidt Source Type: research
Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML
Blood Cancer Journal, Published online: 04 January 2023; doi:10.1038/s41408-022-00774-7Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 4, 2023 Category: Hematology Authors: Xavier Cheng-Hong Tsai Kuo-Jui Sun Min-Yen Lo Feng-Ming Tien Yuan-Yeh Kuo Mei-Hsuan Tseng Yen-Ling Peng Yi-Kuang Chuang Bor-Sheng Ko Jih-Luh Tang Hsun-I Sun Ming-Chih Liu Chia-Wen Liu Chien-Chin Lin Ming Yao Wen-Chien Chou Hsin-An Hou Hwei-Fang Tien Source Type: research
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
Blood Cancer Journal, Published online: 04 January 2023; doi:10.1038/s41408-022-00780-9Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 4, 2023 Category: Hematology Authors: Naseema Gangat Kebede H. Begna Aref Al-Kali William Hogan Mark Litzow Animesh Pardanani Ayalew Tefferi Source Type: research
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
Blood Cancer Journal, Published online: 23 December 2022; doi:10.1038/s41408-022-00776-5Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 23, 2022 Category: Hematology Authors: Noppacharn Uaprasert Palada Pitakkitnukun Nuanrat Tangcheewinsirikul Thita Chiasakul Ponlapat Rojnuckarin Source Type: research
Correction: Chronic lymphocytic leukemia treatment algorithm 2022
Blood Cancer Journal, Published online: 22 December 2022; doi:10.1038/s41408-022-00775-6Correction: Chronic lymphocytic leukemia treatment algorithm 2022 (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 22, 2022 Category: Hematology Authors: Paul J. Hampel Sameer A. Parikh Source Type: research
